ProQR Therapeutics N.V. (PRQR) Form 424B5 — Jul 15, 2026
ProQR Therapeutics N.V. filed a prospectus supplement relating to the proposed resale of up to 3,030,303 ordinary shares by Ginkgo Bioworks Holdings, Inc. The shares being offered were originally issued to Ginkgo Bioworks Holdings in April 2026 pursuant to a Share Purchase Agreement for a purchase price of $5 million, which was paid as service credits under a Master Services Agreement for autonomous lab high-throughput data generation.
Key figures
- Total Debt
- €15,733,000
- Cash Position
- €81,088,000
- Shares Outstanding
- 141121476
- Shares offered
- 3030303
- Selling shareholder stake percent
- 2.1%
Price after filing
1 day: -5.6%7 days: +2.3%30 days: +4.5%
Close on the filing date to close N calendar days later (from $1.77). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.